Remove Blood Pressure Remove Obesity Remove Preserved Ejection Fraction
article thumbnail

Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association

BackgroundThe renal sympathetic nervous system modulates systemic blood pressure, cardiac performance, and renal function. Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We

article thumbnail

What Cardiometabolic Clinicians Can Be Thankful For This Year

Cardiometabolic Health Congress

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF). Eckel, MD, FAHA, FACC at the 19th Annual CMHC.

article thumbnail

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Key Takeaways: Natriuretic Peptides : Useful for diagnosing and monitoring heart failure, particularly HFrEF, but challenging to interpret in patients with obesity due to peptide deficiency. In the U.S.,

CME 103
article thumbnail

Obesity-Related Biomarkers Are Associated With Exercise Intolerance and HFpEF

Circulation: Heart Failure

BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. Fasting blood samples collected at the time of the cardiopulmonary exercise test were used to assay obesity-related biomarkers.

article thumbnail

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52
article thumbnail

Abstract 4139791: A short version of HFD/L-NAME mouse model enabling time-effective proof of concept studies to evaluate drugs targeting the cardiometabolic and mild hypertension associated HFpEF phenotype.

Circulation

Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. l) for 8 weeks. in HFD/L-NAME vs E/A=1.4 ± 0.02

article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)